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doi:10.1016/j.jmii.2011.09.018Background and Purpose: The safety and efficacy of treating serious infections caused by
Staphylococcus aureus with daptomycin in a Taiwanese population were studied.
Methods: A retrospective, multicenter study was performed in Taiwan between December
2007 and June 2009. This study included adult hospitalized patients who had received intrave-
nous daptomycin therapy for infections caused by S aureus. All patients were followed until
discharge from the hospital or death.
Results: A total of 52 patients (males, nZ 44; median age: 62 years) were evaluated. Infec-
tions included complicated skin and soft-tissue infections (nZ 14), catheter-related bacter-
emia (nZ 14), osteomyelitis and septic arthritis (nZ 12), endovascular infections and
endocarditis (nZ 11), and urinary tract infections (nZ 1). Overall, 47 (90.4%) patients were
successfully treated and their clinical symptoms were resolved. Adverse effects related to dap-
tomycin were detected in nine patients, but none were required to discontinue daptomycin.nfectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-
tw (S.-C. Chang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Efficacy of daptomycin for treating staphylococcal infections 53Conclusion: The results support daptomycin as an effective and safe treatment for staphylo-
coccal infections in Taiwanese populations.
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reserved.Introduction
Infections caused by Gram-positive bacteria are increas-
ingly more common and remain one of the leading causes of
morbidity and mortality in hospitalized patients. Many
Gram-positive pathogens are resistant to common classes of
antimicrobial agents, including methicillin and vancomycin.
In the United States (US), the proportion of clinical Staph-
ylococcus aureus isolates with methicillin resistance
increased from 22% in 1995 to 57% in 2001. Vancomycin
resistance was identified in 60% of Enterococcus faecium
isolates, and methicillin resistance was identified in 75% of
coagulase-negative staphylococcal isolates.1 Although
vancomycin remains the first-line drug of choice for treat-
ing methicillin-resistant S aureus (MRSA), recurrent
bacteremia and mortality due to MRSA infections are
increasingly on the rise, despite the use of vancomycin.2,3
In such cases, vancomycin may have an inadequate bacte-
ricidal activity against MRSA, particularly for isolates with
an elevated minimum inhibitory concentration (MIC).4
Daptomycin belongs to a new class of antimicrobial
agentsdthe cyclic lipopeptidesdand demonstrates
a rapid, concentration-dependent bactericidal activity
against a broad spectrum of Gram-positive organisms.
Daptomycin is also fully active against drug-resistant
strains, including MRSA and vancomycin-resistant entero-
cocci (VRE).5 Daptomycin has been approved by the US
Food and Drug Administration (FDA) for treating compli-
cated skin and soft-tissue infections, bacteremia, and right-
sided endocarditis caused by MRSA.6 Therefore, daptomy-
cin appears to be a promising agent for the treatment of
patients with severe infections due to antimicrobial-
resistant, Gram-positive strains of bacteria. Although
there are reports regarding the safety and efficacy of
daptomycin for the treatment of various infections in
Western countries, daptomycin is new to clinical use in
Taiwan and only limited data exist regarding the use of
daptomycin in Asian populations.7e13 In this study, the
safety and efficacy of daptomycin for the treatment of
serious infections were evaluated in hospitalized patients
at nine medical centers in Taiwan.Methods
Patient enrollment
In this investigator-initiated study, we retrospectively
reviewed the medical charts of hospitalized patients who
were treated with daptomycin (Cubicin, Cubist Pharma-
ceuticals, Lexington, MA, USA) at nine medical centers in
Taiwan (National Taiwan University Hospital, Taipei;
Chinese Medical University Hospital, Taichung; KaoshiungMedical University Hospital, Kaoshiung; Taipei Veterans
General Hospital, Taipei; Far-East Memorial Hospital, Pan-
chiao; Jen-Shin Medical Center, Taipei; Chi-Mei Medical
Center, Tainan; Taipei Medical University Hospital, Taipei;
and Triservice General Hospital, Taipei) from December
2007 through June 2009. Patients were treated with dap-
tomycin if they presented with one of the following
criteria: (1) documented MRSA infection that was not
responding to treatment with glycopeptides (i.e., vanco-
mycin or teicoplanin); (2) documented methicillin-
susceptible S aureus (MSSA) or MRSA infection with
a significant allergic reaction to b-lactams or glycopeptides
(e.g., rash, anaphylaxis, etc.); (3) intolerable glycopeptide-
related adverse effects (e.g., hypotension, increase in
serum creatinine level, etc.); or (4) failure of alternative
agents, such as vancomycin, teicoplanin, or linezolid. A
standard case record form was used to collect patient
information, including age, sex, primary and secondary
diagnoses, previous antibiotic treatments, and daptomycin
regimens. Microbiological results were evaluated in all
patients in order to determine the identity of each path-
ogen and its susceptibilities. The isolates were identified
and tested for susceptibility using the Vitek system (bio-
Merieux, Hazelwood, MO, USA). Daptomycin (4e10 mg/kg,
administered intravenously [IV] every 24 hours) was
administered to all patients. The dose was adjusted by the
attending physicians according to the clinical condition of
each patient, the presence of any co-morbidities, and renal
functions. Daptomycin was administered every 48 hours to
patients undergoing hemodialysis or those with a creatinine
clearance <30 mL/min. All patients were hospitalized in
order to complete their IV therapy regimen with dapto-
mycin. The primary outcome was the resolution of the signs
and symptoms associated with infection after discharge
from the hospital.
Antimicrobial susceptibility tests
Susceptibility tests for all isolates were initially performed
using the disc diffusion method, according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines used at
each hospital.14 The MICs of vancomycin and daptomycin
were checked in the isolates obtained from patients who
failed to respond to daptomycin treatment. The MIC of
vancomycin was determined by the broth microdilution
method using Mueller-Hinton broth (BBL, Becton Dickinson,
Sparks, MD, USA). An initial inoculum of 5  105 colony-
forming units (CFU)/mL was utilized, according to CLSI
guidelines.14 When the MIC of daptomycin was tested, the
medium consisted of Mueller-Hinton broth and physiological
levels of calcium (50 mg/mL), as previously recom-
mended.15 S aureus ATCC 29213 was used as a quality
control strain in each run. S aureus Mu3 and Mu50 strains
54 C.-C. Lai et al.were used for comparison with our vancomycin-
intermediate S aureus (VISA) isolates. The MIC for S
aureus ATCC 29213 was within the control ranges reported
by CLSI.14
Definition
Clinical failure was defined as follows: (1) infection-related
death, (2) persistence of the signs and symptoms of infec-
tion after 14 days of therapy with daptomycin, (3) read-
mission to the hospital due to a relapse of the initial
infection, or (4) replacement of daptomycin with other
antimicrobial agents due to persistent infection. Microbio-
logical failure was defined as persistently obtaining positive
cultures from blood or infection sites of patients who were
receiving daptomycin.
Results
During the study period, a total of 52 adult patients (44
males and 8 females) were hospitalized with serious Gram-
positive bacterial infections and received daptomycin
therapy for at least 48 hours. The demographic data are
shown in Table 1. The ages of the patients ranged from 17
to 90 years with a median age of 62 years. Most of the
patients had underlying medical conditions, such as malig-
nancy, congestive heart failure, diabetes mellitus, cere-
brovascular accident, liver cirrhosis, uremia, or chronicTable 1 Demographic characteristics of 52 patients who
received daptomycin therapy
Demographic data No. of patients (%)
Gender; no. of male/female
(% male)
44/8 (84.6)
Mean age, y (range) 62 (17e90)
Body weight, kg (range) 63 (41e83)
Presenting with chronic
medical illness
48 (92.3)
Previous uses of anti-gram positive antibiotics
Oxacillin 5 (9.6)
Vancomycin 24 (46.2)
Teicoplanin 18 (34.6)
Linezolid 5 (9.6)
Median duration of previous
antibiotic use, d (range)
12 (2e165)
Reason for change to daptomycin
Prior antimicrobial
treatment failure
32 (61.5)
Adverse effects from
prior antibiotic use
20 (38.5)
Daptomycin dosage
4 mg/kg/d 11 (21.1)
6 mg/kg/d 30 (57.7)
8 mg/kg/d 8 (15.4)
10 mg/kg/d 3 (5.8)
Median daptomycin treatment,
d (range)
14 (4e116)lung disease. The administered dosages of daptomycin
were 4 mg/kg/d (nZ 11), 6 mg/kg/d (nZ 30), 8 mg/kg/
d (nZ 8), or 10 mg/kg/d (nZ 3). The highest doses were
received by one patient with endocarditis and two patients
with osteomyelitis. Daptomycin was used as replacement
therapy after the failure of previous antimicrobial treat-
ments (nZ 32) or intolerance to prior antibiotic therapies
due to adverse effects (nZ 20). The duration of dapto-
mycin treatment ranged from 4 to 116 days with a median
duration of 14 days.
The types of infections and microbiological results are
shown in Table 2. Complicated skin and soft-tissue infec-
tions (nZ 14) and catheter-related bacteremia (nZ 14)
were the most common infections, followed by osteomye-
litis and septic arthritis (nZ 12), endovascular infection
and endocarditis (nZ 11), and urinary tract infection
(nZ 1). Thirty-six patients (69.2%) were diagnosed with
bacteremia. The identified pathogens included MRSA (47
patients) and MSSA (5 patients). Mixed infections were
found in five patients and included Acinetobacter bau-
mannii (nZ 2), Pseudomonas aeruginosa (nZ 1), Klebsi-
ella pneumoniae (nZ 1), and Escherichia coli (nZ 1).
The clinical and microbiological outcomes are shown in
Tables 2 and 3. Forty-seven (90.4%) patients were treated
successfully. There were no differences in treatment
outcomes between those patients who received < 6 mg/kg/
day and those who received 6 mg/kg/day daptomycin.
(Table 3) Adverse effects related to daptomycin were
detected in nine patients (17.3%), including elevated serum
creatine kinase [CK] levels (nZ 5), leukopenia (nZ 3),
elevated liver aminotransferase levels (nZ 2), elevated
serum creatinine levels (nZ 1), and pruritis (nZ 1). All of
the adverse effects were mild and tolerable. There were no
grade 3 or 4 adverse effects, with the exception of one
patient who developed mild myalgia and an increased
serum CK level that rose from 20 IU/L to 1487 IU/L (normal
upper limit: 167 IU/L). No patient required discontinuation
of daptomycin because of adverse effects. The five patients
with elevated CK levels required 4e13 days (median: 6
days) for their levels to normalize. Five patients failed to
respond to daptomycin treatment (Table 4). Patients who
failed to respond to daptomycin treatment had previously
received a prolonged administration of glycopeptides
(median: 47 days; range: 14e165 days). Three of those
patients had documented MRSA isolates with increased MICs
for both vancomycin (4 mg/mL) and daptomycin (2e4 mg/
mL) recorded during their treatment regimens with van-
comycin and daptomycin.
Discussion
Although vancomycin remains the first-line drug of choice
for treating many antimicrobial-resistant, Gram-positive
bacterial infections, its efficacy against MRSA infections is
declining. The reduced susceptibility of MRSA to vancomy-
cin16 and the inability of antimicrobials to remove of S
aureus-produced biofilms, which may facilitate resistance
by promoting horizontal gene transfer, allow MRSA to
escape lysis and death by vancomycin.17,18 The results
presented here support daptomycin as a highly efficacious
agent for the treatment of serious infections caused by
MRSA in the Taiwanese population.
Table 2 Infections and post-daptomycin treatment
outcomes
Characteristics No. of
patients(%)
Type of infection
Complicated skin and/
or soft-tissue infectiona
14 (26.9)
Catheter-related bacteremia 14 (26.9)
Osteomyelitis and septic arthritisc 12 (23.1)
Bacteremia from endovascular
infection or endocarditisb
11 (21.2)
Urinary tract infectiond 1 (1.9)
Causative microorganism
Methicillin-susceptible
Staphylococcus aureus
5 (9.6)
Methicillin-resistant
Staphylococcus aureus
47 (90.4)
Clinical outcomes (%)
Cure 47 (90.4)
Failure 5 (9.6)
Microbiological outcomes (%)
Eradication 24 (46.2)
Presumed eradication 23 (44.2)
Persisted infection 5 (9.6)
Microbial superinfectione 11 (21.2)
a Includes four patients (three with necrotizing fasciitis and
one with a deep neck infection) diagnosed with bacteremia
b Includes two patients with aortic mycotic aneurysm and nine
with endocarditis
c Includes six patients diagnosed with bacteremia
d Patient had methicillin-resistant Staphylococcus aureus
bacteremia and renal abscess
e Superinfectious pathogens encountered during daptomycin
treatment included Acinetobacter baumannii (nZ 3), Klebsi-
ella pneumoniae (nZ 2), Pseudomonas aeruginosa (nZ 2),
Enterobacter cloacae (nZ 1), Escherichia coli (nZ 1), Serratia
marcescens (nZ 1), and Stenotrophomonas maltophilia
(nZ 1).
Efficacy of daptomycin for treating staphylococcal infections 55With the rising prevalence of MRSA in hospitalized
patients, effective treatment depends on the availability of
antimicrobials with potent activities against these drug-
resistant pathogens. The in vitro potency of daptomycinTable 3 Daptomycin dosages, infection sites, and treatment ou
Cure
Complicated skin and soft-tissue infection 10
Catheter-related bacteremia 1
Osteomyelitis and septic arthritis 0
Bacteremia due to endovascular infection or endocarditis 0
Urinary tract infection 0
a There were no differences in treatment outcomes between those p
kg/d (pZ 0.57).has been demonstrated against a wide range of aerobic and
anaerobic Gram-positive bacteria, including MRSA, VISA,
methicillin-resistant coagulase-negative staphylococci
(MRCNS), and VRE.19 In a time-kill study performed on
MRSA, MRSE, VRE, and VISA, daptomycin demonstrated
a more rapid bactericidal activity (3 log CFU/mL within 8
hours) than vancomycin, linezolid, and quinupristin-dalfo-
pristin.20,21 Daptomycin also exhibits a dose-dependent,
postantibiotic effect against E. faecalis and S aureus that
lasts between 1 and 6 hours.22 These characteristics suggest
that daptomycin is a promising agent for use against various
Gram-positive bacterial infections.
The approved dose of daptomycin for complicated skin
and soft-tissue infections is 4 mg/kg.7 A previously reported
clinical study demonstrates the efficacy of higher doses
(6 mg/kg) of daptomycin for treating bacteremia and
infective endocarditis.8 Most patients in this study received
6 mg/kg. Compared to other reports, the use of higher
dosages of daptomycin for patients with severe MRSA
infections has been shown to be safe and well tolerated,
even for longer durations of therapy.10e13,21,23 The phar-
macokinetic profile and concentration-dependent antimi-
crobial properties of daptomycin suggest that higher doses
(6 mg/kg/day) may be beneficial for treating severe
infections.
Resistance to daptomycin in MRSA isolates has been re-
ported in patients with bacteremia and osteomyelitis.24e27
Interestingly, almost all of these patients had received
previous treatment with vancomycin. Not unlike other
studies, our results also demonstrate a correlation between
reduced daptomycin susceptibility and vancomycin resis-
tance in VISA after prolonged vancomycin therapy.28e31 A
thickened cell wall may contribute to the resistance of S
aureus against daptomycin.27 Although glycopeptide-
intermediate S aureus (GISA) has been noted since 1997,
the isolation of GISA has been rare until quite recently
(0.3% of all strains of S aureus).32 As reported in the
SENTRY Antimicrobial Surveillance Program, of 15 identified
GISA isolates, 86.7% were susceptible to daptomycin.33 Out
of almost 10,000 isolates of S aureus tested, only four
(0.04%) had a daptomycin MIC of 2 mg/mL (all four of these
isolates were glycopeptide-susceptible S aureus) and only
two (0.02%) GISA isolates were identified (vancomycin MIC:
4 mg/mL; daptomycin MIC: 0.5e1 mg/mL).34e36 Although the
strains of S aureus that are insusceptible to daptomycin are
rare, our results recommend testing MRSA isolates fortcomesa
Daptomycin dosage (mg/kg/d)
4 6 8 10
d Failed Cured Failed Cured Failed Cured Failed
0 3 0 1 0 0 0
0 12 0 1 0 0 0
0 5 1 4 0 2 0
0 4 4 2 0 1 0
0 1 0 0 0 0 0
atients who received <6mg/kg/d and those who received 6 mg/
Table 4 Clinical and microbiologic characteristics of patients who failed to respond to daptomycin treatment (nZ5)
Case no.
age/sex
[Ref.]
Underlying
systemic illness
Prior antibiotic
usage/reason for
daptomycin
Infections Pathogen Daptomycin
dosage,
duration
Reason of failure
of daptomycin
treatment
1.
66/M
[28]
Chronic hepatitis
C with cirrhosis,
end-stage renal
disease
postendovascular
graft
Vancomycin and
teicoplanin, 47 d/
Treatment failure
Graft septic
thromboplebitis
with bacteremia,
left-sided
endocarditis
MRSA
(VISA)a
6 mg/kg/
q2d,
12 d
Persistent MRSA
bacteremia
died of candidemia,
septic shock and
multiple organ
failure
2.
57/M
[29]
Congestive heart
failure,
post-heart
transplantation
Vancomycin and
teicoplanain,
165 d/
Treatment failure
Mycotic aortic
aneurysm with
bacteremia
MRSA
(VISA)a
6 mg/kg/d,
4 d
Persistent MRSA
infection, died of
aortic aneurysm
rupture
3.
17/F
Traffic accident,
post-knee joint
prosthesis
implantation
Vancomycin,
teicoplanin,
and linezolid,
77 d/
Treatment failure
Osteomyelitis of
femoral prosthesis
MRSA 6 mg/kg/d,
62 d
Prosthesis not
removed, persistent
MRSA infection
4.
85/M
[30]
Chronic kidney
disease,
long-term total
parenteral nutrition
Vancomycin plus
gentamicin,
14 d/
Treatment
faiure
Catheter-related
bacteremia,
infective endocarditis,
septic shock
MRSA
(VISA)a
6 mg/kg/
q2d,
13 d
No surgical
intervention
died of persistent
MRSA infection,
and multiple organ
failure
5.
86/M
[31]
Coronary arterial
disease, diabetes,
end-stage renal
disease
Vancomycin
plus rifampin,
19 d/
Treatment
failure
Hickman
catheter-related
bacteremia,
infective endocarditis,
lung abscess,
septic shock
MRSA 6 mg/kg/
q2d,
5 d
Successful treated
with linezolid,
fusidic acid, and
teicoplanin
a Elevated minimal inhibitory concentrations of vancomycin (4 mg/mL) and daptomycin (2e4 mg/mL) of three Staphylococcus aureus
isolates that were identified.
56 C.-C. Lai et al.susceptibility to daptomycin and glycopeptides, especially
those obtained from patients who initiate daptomycin after
prolonged glycopeptide therapy.
The adverse effects of daptomycin, including increased
CK levels and associated myopathy, are concerning.7,10e13
However, in this case series, only one patient with an
elevated CK level > 5 the normal upper limit and gener-
alized myalgia was identified. No patient was required to
discontinue daptomycin treatment due to its adverse
effects. The tolerability of long-term treatment is an
important concern for patients with severe infections, such
as infective endocarditis and septic arthritis/osteomyelitis;
these patients must be treated with antibiotics for 4e6
weeks in order to completely eradicate the pathogen. The
high tolerability and safety of daptomycin make it a useful
antimicrobial agent against difficult-to-treat infections.
In conclusion, this report demonstrates that daptomycin
is safe and well tolerated by Taiwanese populations, even
for extended treatment periods. Daptomycin may prove to
be an effective option for treating bacteremia and serious
drug-resistant staphylococcal infections. Increased dosages
and the susceptibility of MRSA and/or VISA isolates to
daptomycin are important considerations that warrant
further study, especially when considering daptomycin as
a salvage therapy for MRSA and/or VISA bacteremia with
difficult-to-eradicate foci.References
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